Dytfell et al. reported that increased TXNDC5 expression in plasma cells and serum is related to a poor response to bortezomid-based therapy in patients with newly diagnosed MM and in those with relapsed MM. This evidence concerns the gene TXNDC5 and Miyoshi myopathy.